Kidiamix G (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

The mixture supplies the building blocks required for protein synthesis, supports nitrogen balance, and serves as precursors for metabolic pathways. By delivering these amino acids directly into the bloodstream, it bypasses the need for intestinal absorption and helps maintain cellular function during periods of catabolic stress.

The dose of Kidiamix G is individualized by the prescribing clinician based on the patient’s weight, clinical condition, renal and hepatic function, and overall nutritional goals. Healthcare professionals calculate the infusion rate and total daily amount to meet specific protein and caloric requirements.

Safety data for Kidiamix G in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kidiamix G offers a comprehensive blend of essential and non‑essential amino acids in a single sterile solution, which can simplify formulation compared with multi‑component kits. Its EU‑origin manufacturing ensures compliance with GMP standards, while alternative products may vary in amino‑acid composition, concentration, or regulatory status.

Kidiamix G must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or vigorously shaken. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the administration protocol.

Kidiamix G is administered intravenously as a sterile solution for injection. It is typically infused through a dedicated line or a compatible infusion set, following aseptic technique. The infusion rate is set by the clinician according to the prescribed dosage and patient tolerance.

Serious risks include anaphylactic reactions, severe hypotension, metabolic acidosis, hepatic dysfunction, acute renal failure, and profound electrolyte disturbances. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Kidiamix G is contraindicated in patients with known hypersensitivity to any of its amino‑acid components, those with uncontrolled severe metabolic disorders, or individuals for whom intravenous amino‑acid administration is medically inappropriate. Clinical judgment should guide exclusion in cases of severe organ dysfunction.